Metabolic Health: What Cardio IQ-Style Testing Reveals

Standard cholesterol panels miss what's actually driving cardiovascular risk in most patients. Advanced metabolic testing reveals the patterns standard medicine doesn't see — and changes how the conversation goes.

What patients tell us

“My standard labs come back fine — cholesterol is in range, A1C is normal, blood pressure is okay. But I'm gaining weight in my middle, my energy is dropping, my workouts don't produce results, and I feel like something is shifting metabolically. My doctor says we'll watch it. I want to know what's actually happening before something gets harder to address.”

Why standard metabolic evaluation falls short

The cardiovascular and metabolic evaluation most patients receive in primary care looks at a relatively small number of markers — total cholesterol, LDL-C, HDL-C, triglycerides, fasting glucose, hemoglobin A1C. These markers identify patients with overt disease. They miss patients who are years to decades away from overt disease but already showing the metabolic changes that precede it.

Standard LDL-C calculation is increasingly recognized as an inadequate marker of cardiovascular risk. Two patients with identical LDL-C values can have substantially different risk because LDL particle number and size matter more than the cholesterol the particles carry. Fasting glucose and A1C identify patients who already have prediabetes or diabetes — by definition, patients whose pancreatic beta cells have started to fail. The metabolic disruption that precedes these abnormalities develops over years before fasting glucose rises.

What advanced metabolic testing reveals

Cardio IQ and similar advanced metabolic panels include markers that fundamentally change the clinical picture. Lipoprotein subfractionation reveals LDL particle number, LDL particle size, HDL functional measures, and lipoprotein(a). Fasting insulin identifies insulin resistance years before fasting glucose abnormalities appear. Expanded inflammatory profiles characterize the inflammatory contribution to cardiovascular risk. Markers of glucose dysregulation identify metabolic dysfunction that fasting measures miss. Adipokines, nutrient markers, expanded thyroid evaluation, and sex hormone patterns complete the picture.

What the patterns mean clinically

Several specific patterns recur in patients whose standard labs have been called normal: insulin resistance with compensatory hyperinsulinemia; atherogenic lipid pattern with elevated particle number and small dense LDL; inflammatory cardiovascular risk; subclinical thyroid contribution to metabolic dysfunction; and nutrient and cofactor insufficiencies.

How iHeal uses advanced metabolic evaluation

The clinical approach uses advanced testing strategically — not as a comprehensive screen for every patient, but selected based on clinical question and history. Interpretation considers patterns rather than single values in isolation. Treatment matches the documented findings: insulin resistance responds to dietary patterns that reduce insulin demand, exercise, and in some cases pharmacologic support; atherogenic lipid patterns may warrant statin therapy alongside lifestyle modification; inflammatory contribution responds to addressing the underlying drivers; thyroid contribution warrants the broader evaluation discussed on the Hashimoto's page.

Dr. Matthew Everett, MD

Pro Tip · From Dr. Everett

Matthew Everett, MDEnvironmental Medicine · IFMCP

The clinical approach uses advanced testing strategically — not as a comprehensive screen for every patient, but selected based on clinical question and history. Interpretation considers patterns rather than single values in isolation. Treatment matches the documented findings: insulin resistance responds to dietary patterns that reduce insulin demand, exercise, and in some cases pharmacologic support; atherogenic lipid patterns may warrant statin therapy alongside lifestyle modification; inflammatory contribution responds to addressing the underlying drivers; thyroid contribution warrants the broader evaluation discussed on the Hashimoto's page.

Sources & Further Reading

Concerned this applies to you?

A consultation is where we figure out whether metabolic health is actually contributing to your symptoms — and what to do about it.

On This Page

Metabolic Health: What Cardio IQ-Style Testing Reveals

Standard cholesterol panels miss what's actually driving cardiovascular risk in most patients. Advanced metabolic testing reveals the patterns standard medicine doesn't see — and changes how the conversation goes.

What patients tell us

“My standard labs come back fine — cholesterol is in range, A1C is normal, blood pressure is okay. But I'm gaining weight in my middle, my energy is dropping, my workouts don't produce results, and I feel like something is shifting metabolically. My doctor says we'll watch it. I want to know what's actually happening before something gets harder to address.”

Why standard metabolic evaluation falls short

The cardiovascular and metabolic evaluation most patients receive in primary care looks at a relatively small number of markers — total cholesterol, LDL-C, HDL-C, triglycerides, fasting glucose, hemoglobin A1C. These markers identify patients with overt disease. They miss patients who are years to decades away from overt disease but already showing the metabolic changes that precede it.

Standard LDL-C calculation is increasingly recognized as an inadequate marker of cardiovascular risk. Two patients with identical LDL-C values can have substantially different risk because LDL particle number and size matter more than the cholesterol the particles carry. Fasting glucose and A1C identify patients who already have prediabetes or diabetes — by definition, patients whose pancreatic beta cells have started to fail. The metabolic disruption that precedes these abnormalities develops over years before fasting glucose rises.

What advanced metabolic testing reveals

Cardio IQ and similar advanced metabolic panels include markers that fundamentally change the clinical picture. Lipoprotein subfractionation reveals LDL particle number, LDL particle size, HDL functional measures, and lipoprotein(a). Fasting insulin identifies insulin resistance years before fasting glucose abnormalities appear. Expanded inflammatory profiles characterize the inflammatory contribution to cardiovascular risk. Markers of glucose dysregulation identify metabolic dysfunction that fasting measures miss. Adipokines, nutrient markers, expanded thyroid evaluation, and sex hormone patterns complete the picture.

What the patterns mean clinically

Several specific patterns recur in patients whose standard labs have been called normal: insulin resistance with compensatory hyperinsulinemia; atherogenic lipid pattern with elevated particle number and small dense LDL; inflammatory cardiovascular risk; subclinical thyroid contribution to metabolic dysfunction; and nutrient and cofactor insufficiencies.

How iHeal uses advanced metabolic evaluation

The clinical approach uses advanced testing strategically — not as a comprehensive screen for every patient, but selected based on clinical question and history. Interpretation considers patterns rather than single values in isolation. Treatment matches the documented findings: insulin resistance responds to dietary patterns that reduce insulin demand, exercise, and in some cases pharmacologic support; atherogenic lipid patterns may warrant statin therapy alongside lifestyle modification; inflammatory contribution responds to addressing the underlying drivers; thyroid contribution warrants the broader evaluation discussed on the Hashimoto's page.

Dr. Matthew Everett, MD

Pro Tip · From Dr. Everett

Matthew Everett, MDEnvironmental Medicine · IFMCP

The clinical approach uses advanced testing strategically — not as a comprehensive screen for every patient, but selected based on clinical question and history. Interpretation considers patterns rather than single values in isolation. Treatment matches the documented findings: insulin resistance responds to dietary patterns that reduce insulin demand, exercise, and in some cases pharmacologic support; atherogenic lipid patterns may warrant statin therapy alongside lifestyle modification; inflammatory contribution responds to addressing the underlying drivers; thyroid contribution warrants the broader evaluation discussed on the Hashimoto's page.

Sources & Further Reading

Concerned this applies to you?

A consultation is where we figure out whether metabolic health is actually contributing to your symptoms — and what to do about it.

On This Page